AurKa Pharma Inc., based in Montréal, Québec, is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Ventures VII. AurKa Pharma Inc. plans to develop, to proof-of-concept, a compound originally discovered through one of Eli Lilly and Company’s (Lilly) research and development programs, with the potential to treat certain types of solid tumors, including small cell lung cancer and treatment resistant breast cancer.
As of September 2016, the biopharmaceutical asset has completed GLP toxicology studies. AurKa Pharma Inc. plans to begin clinical development in Q3-2017. Once cleared for clinical development by regulatory authorities, the AurKa Pharma Inc. compound will be tested directly alone in solid tumors.
Later on, the compound may be tested in one of a number of additional cancer indications with the goal of providing a clinical proof-of-concept of efficacy for cancer patients.